Cancer Chemotherapy by Infusion

1. Front Matter

   Pages i-xxvii

   PDF

2. Rationale and Technical Aspects

   1. Front Matter

      Pages 1-1

      PDF

   2. Introduction to the Concept and Practice of Infusion Chemotherapy

      • Jacob J. Lokich

      Pages 3-11

   3. Experimental Rationale for Continuous Infusion Chemotherapy

      • Mark J. Ratain, Nicholas J. Vogelzang

      Pages 12-34

   4. The Clinical Pharmacology of Infusional Chemotherapy

      • Gregory A. Curt, Jerry M. Collins

      Pages 35-40

   5. Drug Administration Systems for Infusion Chemotherapy

      • Elton M. Tucker

      Pages 41-58

   6. Technical Aspects of Vascular Access for Infusional Chemotherapy

      • A. Bothe Jr., J. Daly

      Pages 59-73

   7. Nursing Management of Infusion Catheters

      • Cheryl L. Moore

      Pages 74-99

   8. Pharmaceutical Issues in Infusion Chemotherapy Stability and Compatibility

      • John A. Benvenuto, Stephen C. Adams, Harish M. Vyas, Roger W. Anderson

      Pages 100-113

3. Chemotherapeutic Agents

   1. Front Matter

      Pages 115-115

      PDF

   2. Antipyrimidines: 5-Fluorouracil and 5-Fluoro-2′-Deoxyuridine

      • Michael J. O’Connell

      Pages 117-122

   3. Methotrexate

      • Carmen J. Allegra, Gregory A. Curt

      Pages 123-129

   4. Anthracyclines

      • Sewa S. Legha, Gabriel N. Hortobagyi, Robert S. Benjamin

      Pages 130-144

   5. Cisplatin, Platinum Analogues, and Other Heavy Metal Complexes

      • Stephen P. Ackland, Nicholas J. Vogelzang

      Pages 145-160

   6. Cytosine Arabinoside

      • Gregory A. Curt, Carmen J. Allegra, Bruce D. Cheson

      Pages 161-166

   7. Periwinkle Alkaloids I: Vinblastine and Vindesine

      • Mark J. Ratain, Nicholas J. Vogelzang, Gerald P. Bodey

      Pages 167-180

   8. Periwinkle Alkaloids II: Vincristine

      • Don V. Jackson Jr.

      Pages 181-199

   9. Bleomycin

      • Robert B. Catalano, Robert L. Comis

      Pages 200-210

   10. The Epipodophyllotoxins: VP-16 and VM-26

       • Nancy Phillips, Robert L. Comis

       Pages 211-220

   11. Alkylating Drugs and Other Agents

       • Jacob J. Lokich

       Pages 221-230

Chemotherapy for-cancer is in a state of evolution. Because some cancers can now be cured with chemotherapy as a singular modality, this therapy can no longer be viewed as simply a palliative contribution. Chemotherapy has assumed an important role as an adjuvant to other modalities, including both surgery and radiation therapy. For some tumors, the primary application of chemotherapy in a combined modality approach to curative therapy has resulted in the application of less radical surgery while achieving substantial of relatively rare tumors such as cure rates. Nonetheless, with the exception childhood tumors, hematologic malignancies, and testicular cancer, the effec­ tiveness of chemotherapy in most tumors is severely limited. At the cellular level, greater understanding of the specific mechanism of tumor cell killing and of the phenomenon of drug resistance are elusive, critical ingredients in the improvement of effectiveness in cancer chemotherapy. Prolonging the exposure time of the tumor cell to drugs is a concept that was addressed in the early phases of the development of chemotherapy. How­ ever, technological limitations inhibited the broader application of chemother­ apy by infusion until recent years. Also, the convenience of intermittent ther­ apy on an outpatient basis, with the predominant theory of drug effect based on a dose response as well as the proven effectiveness of this schedule in some tumors, has slowed the process of subjecting infusion chemotherapy to the rigors of clinical trials.

• Staging
• brain tumors
• carcinoma
• cell
• classification
• clinical trial
• esophagus
• liver
• liver tumor
• lymphoma
• melanoma
• metastasis
• ovarian cancer
• pharmacology
• tumor

Policies and ethics